Chinese new endocrine drug developer Visen Pharma announced the completion of US$150 million in Series B financing, led by Sequoia China Fund. Aobo Capital, Sherpa Investment, Cormorant, HBM Healthcare Investments, Dingfeng Biotech Capital, Logos Capital, Chenling Capital also participated in the investment. Existing shareholders Ascendis Pharma A/S, Vivo Capital, Sofinnova Investments continued to invest in […]

Sequoia China Leads $150 Million Round In Drug Developer Visen Pharma comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.


Visit the original source and full text: China Money Network